The HCC treatments also reduced the expression levels of FoxO3a, NF-κB, Atrogin, and MuRF-1 by 1.4, 1.5, 1.9, and 6.5 fold compared to TNF-α. This evidence concerns the gene TNF and hepatocellular carcinoma.